In vitamin K deficiency or intake of oral anticoagulants (vitamin K-antagonists) the s;mthesis of the blood clotting factors of the prothrombin complex is blocked in one of its last steps. Pol;ryeptide chain synthesis on the ribosomal level (7) is not hampered, and the demonstration of precursor prod.ucts, which hypothetically could resemble the clotting factors, has been attempted in several investigations (2, 3, 5, 8) . Immunochemical methods enabled Ganrot and Nil6hn (2) to demonstrate two populations of prothrombin molecules in coumarin plasma, and Josso et al. (8) found in excess of immunologically demonstrable prothrombin over prothrombin activity. The present report concerns the demonstration of a precursor molecule that resembles factor fX in its antigenic properties.
Methods
Factor fX (PTC) assays were carried out with a one-stage kaolin-phospholipid activa.ted principle (14) . clotting times were read automatically with coagulometers (DEPEX, de Bilt, The Netherlands). The PTC-inhibitor plasma was kindly supplied by Dr. Harold R oberts of Chapel Hill. The inhibitor plasma was received on 27 Jrly 1969 and stored at -80o C. It was used in a dilution of 1:2 in the method for measuring PTO-inhibitor neutralizing capacity as deseribed by Roberts ei al. (1, 12) , The titre of the inhibitor did not alter during more fhan a year of storage.
Results
rn Table 1 it can be seen that a coumarin plasma, in this case obtained from a patient (No.7) with virtually no factor IX activity in the plasma due to suicidal intake of the long-acting coumarin-congener phenprocoumon, contains a large amount of PTCinhibitor neutralizing material. This particular plasma also had less than Lo/ofactorlI, vrr, and X activity. Another patient (No.8), with 8.5% factor rX activity (Thrombotest 300 sec due to overdosage oi phenprocoumon), showed 22% PTC-INC (PTC .Inhibitor -lfleutralizing Capacity). BaSoo adsorption removes not only "clottable" factor rX (No.11) but also PTC-rNC (No.10) from oxalated plasma. al(oH)s has the same action on citrated plasma. PTC-INC is not mimickeil by the presence of phenprocoumon, as can be judged from the result obtained with plasma No. 12, which rvas composed of sample No.6 to which phenprocoumon was added in uitro in a concentration of 10 pgiml. This concentration is comparable to the concentration of the coumarin-congener in samples 7 and 8 (about 7 lt"glml), assayed according to Seiler and Duckert (13). 
Discussion
Oral anticoagulants take effect not only by depressing coagulation factors II, VII, IX, and X, due to an anti-vitamin-K action, but also cause the appearance of a protein called PIVKA (Protein lnduced by Zitamin K,4bsence) (5). In prothrombin time methods using thromboplastins prepared from brain from various species (9), this protein exerts a competitive inhibitory effect. The site of inhibition in the reaction sequence of coagulation has been localized at the conversion of factor X from a proenzyme into an active moiety (4).
It is thought that the protein in question is a precursor of one or mor€; of the coagulation factors of the prothrombin complex. During the blockade of the vitamin-Kdependent step assumed to be responsible for conversion of the precursor into a coagulation factor (II, VII, IX, or X), sS,rrthesis of the precursor in hepatic cells leads to overflow of the precursor into the circulation. On the basis of this hlpothesis coagulation-factor like protein could be expected to circulate in vitamin-K-deficiency or oral anticoagulation. In attempting to further define the precursor, Ganrot and Nil6hn (2) demonstrated a prothrombin in coumarin plasma with a electrophoretic mobility differing from the normal. They also reported defective adsorption of PIVKA onto BaSOn, but this finding seems doubtful, because they used citrated plasma and adsorbecl urith 10 mg BaSOoiml. Under these conditions, the adsorption of both the prothrombin complex and PIVKA is known to be incomplete.
Another indication of the presence of a prothrombin-like material in anticoagulated human plasma is the finding of material that develops thrombin activity at a rate much more slowly than prothrombin itself (6) . Investigations by both Prentice (10) and Prydz (11) clearly demonstrated an excess of immunologically detectable factor X over factor X activity in anticoagulated samples.
3r4
The investigation reported here shorvs that a signiflcant amount of PTC-inhibitor neutralizing material can be demonstrated in anticoagulated human plasma. The few selected samples used in this study contain very low factor IX activity and thus enabled us to make economic use of the PTC-inhibitor. Hisher levels of factor IX activity make the interpretation of the difference from the residual factor IX activity reflecting the amount of PTC-inhibitor neutralizing material progressively more difficult (and therefore create a statistical problem).
The existence of protein induced by vitamin K absence or antagonist has been demonstrated in different ways: as an in-h.ibitor of prothrombin time t;rye estimation, as an abnormal prothrombin, as anti-factor-Il cross-reacting material, as antiJactor-X cross-reacting material, and, now as PTO-inhibitor neutralizing capacity. We do not as yet want to assume the existence of a different precursor for each of the vitamin K dependent coagulation factors, because the activities mentioned might all be due to a single type of molecule. The possibility that more than one t5rye of PIVKA exists must, be taken into consideration.
Summary
By means of the PTO-inhibitor neutralizing test (12) a significant excess of PTC (factor IX)-like material over factor IX activity could be demonstrated in human coumarin plasma. This cross-reacting material is considered to be a precursor of one or all of the clotting factors of the prothrombin complex.
R6sum6
A l'aide du test de neutralisation du PTC (12) on met en 6vidence, dans le plasma d'individus trait6s aux d6riv6s de la coumarine, un excds marqu6 de mat6riel semblable au PTC (facteur IX) par rapport au facteur IX procoagulant. Ce mat6riel interf.6ranl est consid6r6 comme 6tant un pr6curseur d'un ou de tous les facteurs du complexe de la prothrombine.
Zusammenfassung
Mit Hilfe des PTC-Inhibitorneutralisationstestes (12) konnte im menschlichen Coumarin-Plasma ein signifikanter UberschuB an PT0-(n'aktor IX)-ri,hnlichem Material gegeniiber der Gerinnungsfaktor-IX-Aktivitti,t nachgewiesen werden. Es wird angenommen, daB dieses kreuzreagierende Material eine Vorstu{e eines oder aller Gerinnungsfaktoren des Prothrombinkomplexes ist.
